⚕ GalenOps field
←

SITE013-0196

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2022-10-23

AEs
7
Serious
1
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Anaemia — outcome: UNKNOWN; onset 2022-12-12 (study day 40); relationship: N

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-18 (study day 108); relationship: not assessed

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-02-21 (study day 111); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-03-15 (study day 133); relationship: not assessed

severe serious assessed

Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-19 (study day 137); relationship: not assessed; serious criteria: life-threatening

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-04-07 (study day 156); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-05-24 (study day 203); relationship: not assessed

Data queries

No data queries.